Martin Hindle, Chairman of the newly formed company Porton Biopharma Limited (PBL), today opened an extension to its Pharmaceutical stores (Pharm-Stores).
PBL manufactures a number of key bio-pharmaceutical products including Erwinase®, a drug that is principally used to cure childhood leukaemia around the world. The company was commercialised out of Public Health England earlier this year to enable it to have more operational freedom, which includes the ability to invest in key facilities.
Commenting on the opening Mr Hindle said …“This new extension is the first physical demonstration of the belief that we all have in the company and our vision for the future. By building up our capacity it will enable us to grow the business, thereby securing the future for our staff and providing more life-saving products”.
The £1.3 million extension adds an additional 168m2 for goods receipt/booking-in and quarantine storage to the existing building. This unit handles all the incoming raw materials and disposables to enable them to be checked and approved for use in the highly regulated pharmaceutical manufacturing plants on site. In addition to the extension there is also an improved access ramp, as well additional external corrosive and flammable stores